Tumor Biology

, Volume 37, Issue 8, pp 10877–10882 | Cite as

Telomere length in peripheral leukocytes is associated with immune cell tumor infiltration and prognosis in colorectal cancer patients

  • Ulrika Svenson
  • Åke Öberg
  • Roger Stenling
  • Richard Palmqvist
  • Göran Roos
Original Article


Telomeres are protective structures at the end of chromosomes, essential for chromosomal integrity. A large number of studies have investigated leukocyte telomere length as a possible risk marker for various cancers, colorectal cancer (CRC) included. In contrast, studies investigating leukocyte telomere length in relation to CRC survival are lacking. We previously reported that relative telomere length (RTL) of leukocytes collected at diagnosis predicted survival in patients with breast and kidney cancer. We suggested that these findings might reflect various immunological mechanisms, affected by the presence of a tumor. In the present study, leukocyte RTL was examined in relation to immune cell tumor infiltration and prognosis in 130 patients with CRC diagnosis. RTL was measured with a well-established qPCR method. We found that patients with the highest degree of lymphocyte tumor infiltration had shorter leukocyte RTL. Consistent with our previous findings, short RTL was a favorable prognostic marker in univariate survival analysis. In the current study, RTL did not remain as an independent predictor in multivariate survival analysis, when including metastatic status in the model. However, a non-significant trend towards a similar telomere-associated survival pattern was observed in patients with limited disease. In contrast, for patients who died of other causes than CRC, short RTL was associated with significantly shorter survival time. To our knowledge, this is the first study to investigate an association between leukocyte RTL, immune cell tumor infiltration, and cancer-specific survival in CRC patients. Larger studies are warranted to verify these findings.


Telomere length Peripheral leukocytes Colorectal carcinoma Immune cell infiltration 


Compliance with ethical standards

Conflicts of interest



  1. 1.
    Cong YS, Wright WE, Shay JW. Human telomerase and its regulation. Microbiol Mol Biol Rev. 2002;66:407–25.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Kaszubowska L. Telomere shortening and ageing of the immune system. J Physiol Pharmacol. 2008;59 Suppl 9:169–86.PubMedGoogle Scholar
  3. 3.
    Svenson U, Nordfjäll K, Stegmayr B, Manjer J, Nilsson P, Tavelin B, et al. Breast cancer survival is associated with telomere length in peripheral blood cells. Cancer Res. 2008;68:3618–23.CrossRefPubMedGoogle Scholar
  4. 4.
    Svenson U, Ljungberg B, Roos G. Telomere length in peripheral blood predicts survival in clear cell renal cell carcinoma. Cancer Res. 2009;69:2896–901.CrossRefPubMedGoogle Scholar
  5. 5.
    Svenson U, Grönlund E, Söderström I, Sitaram RT, Ljungberg B, Roos G. Telomere length in relation to immunological parameters in patients with renal cell carcinoma. PLoS One. 2013;8:e55543.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Liu HQ, An JZ, Liu J, Yang YF, Zhang HX, Zhao BY, et al. Leukocyte telomere length predicts overall survival in hepatocellular carcinoma treated with transarterial chemoembolization. Carcinogenesis. 2012;33:1040–5.CrossRefPubMedGoogle Scholar
  7. 7.
    Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893–91.CrossRefPubMedGoogle Scholar
  8. 8.
    Boardman LA, Litzelman K, Seo S, Johnson RA, Vanderboom RJ, Kimmel GW, et al. The association of telomere length with colorectal cancer differs by the age of cancer onset. Clin Transl Gastroenterol. 2014;5:e52.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Riegert-Johnson DL, Boardman LA, Crook JE, Thomas CS, Johnson RA, Roberts ME. Shorter peripheral blood telomeres are a potential biomarker for patients with advanced colorectal adenomas. Int J Biol Markers. 2012;27:e375–80.CrossRefPubMedGoogle Scholar
  10. 10.
    Seguí N, Guinó E, Pineda M, Navarro M, Bellido F, Lázaro C, et al. Longer telomeres are associated with cancer risk in MMR-proficient hereditary non-polyposis colorectal cancer. PLoS One. 2014;9:e86063.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Qin Q, Sun J, Yin J, Liu L, Chen J, Zhang Y, et al. Telomere length in peripheral blood leukocytes is associated with risk of colorectal cancer in Chinese population. PLoS One. 2014;9:e88135.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Cui Y, Cai Q, Qu S, Chow WH, Wen W, Xiang YB, et al. Association of leukocyte telomere length with colorectal cancer risk: nested case-control findings from the Shanghai Women’s Health Study. Cancer Epidemiol Biomarkers Prev. 2012;21:1807–13.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Chen Y, Qu F, He X, Bao G, Liu X, Wan S, et al. Short leukocyte telomere length predicts poor prognosis and indicates altered immune functions in colorectal cancer patients. Ann Oncol. 2014;25:869–76.CrossRefPubMedGoogle Scholar
  14. 14.
    Nordfjäll K, Osterman P, Melander O, Nilsson P, Roos G. hTERT (−1327)T/C polymorphism is not associated with age-related telomere attrition in peripheral blood. Biochem Biophys Res Commun. 2007;358:215–8.CrossRefPubMedGoogle Scholar
  15. 15.
    Cawthon RM. Telomere measurement by quantitative PCR. Nucleic Acids Res. 2002;30(10):e47.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Jass JR. Lymphocytic infiltration and survival in rectal cancer. J Clin Pathol. 1986;39:585–9.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Sanders JL, Newman AB. Telomere length in epidemiology: a biomarker of aging, age-related disease, both, or neither? Epidemiol Rev. 2013;35:112–31.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pagès C, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313:1960–4.CrossRefPubMedGoogle Scholar
  19. 19.
    Ogino S, Nosho K, Irahara N, Meyerhardt JA, Baba Y, Shima K, et al. Lymphocytic reaction to colorectal cancer is associated with longer survival, independent of lymph node count, microsatellite instability, and CpG island methylator phenotype. Clin Cancer Res. 2009;15:6412–20.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Dahlin AM, Henriksson ML, Van Guelpen B, Stenling R, Oberg A, Rutegård J, et al. Colorectal cancer prognosis depends on T-cell infiltration and molecular characteristics of the tumor. Mod Pathol. 2011;24:671–82.CrossRefPubMedGoogle Scholar
  21. 21.
    Galon J, Mlecnik B, Bindea G, Angell HK, Berger A, Lagorce C, et al. Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours. J Pathol. 2014;232:199–209.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2016

Authors and Affiliations

  • Ulrika Svenson
    • 1
  • Åke Öberg
    • 2
  • Roger Stenling
    • 1
  • Richard Palmqvist
    • 1
  • Göran Roos
    • 1
  1. 1.Department of Medical BiosciencesUmeå UniversityUmeåSweden
  2. 2.Department of Surgical and Perioperative SciencesUmeå UniversityUmeåSweden

Personalised recommendations